Carcinoma, Renal Cell Clinical Trials

12 recruiting

Carcinoma, Renal Cell Trials at a Glance

12 actively recruiting trials for carcinoma, renal cell are listed on ClinicalTrialsFinder across 6 cities in 14 countries. The largest study group is Phase 2 with 5 trials, with the heaviest enrollment activity in Seoul, Houston, and Austin. Lead sponsors running carcinoma, renal cell studies include Merck Sharp & Dohme LLC, Jinling Hospital, China, and IRCCS San Raffaele.

Browse carcinoma, renal cell trials by phase

Treatments under study

About Carcinoma, Renal Cell Clinical Trials

Looking for clinical trials for Carcinoma, Renal Cell? There are currently 12 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Carcinoma, Renal Cell trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Carcinoma, Renal Cell clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 112 of 12 trials

Recruiting
Phase 3

A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)

Carcinoma, Renal Cell
Merck Sharp & Dohme LLC758 enrolled3 locationsNCT07489495
Recruiting
Phase 3

Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)

Carcinoma, Renal CellVon Hippel-Lindau Disease
Merck Sharp & Dohme LLC450 enrolled9 locationsNCT07405164
Recruiting
Phase 1Phase 2

Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma

Carcinoma, Renal Cell
Oncorena AB75 enrolled5 locationsNCT05287945
Recruiting
Phase 1Phase 2

Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

Metastatic Renal Cell CarcinomaCarcinoma, Renal CellAdvanced Renal Cell Carcinoma+8 more
Pfizer224 enrolled49 locationsNCT07227415
Recruiting
Phase 1Phase 2

Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination With Sunitinib in Patients With TKIs-resistant RCC

Carcinoma, Renal Cell
State University of New York at Buffalo28 enrolled1 locationNCT06222593
Recruiting

Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma

CarcinomaCarcinoma, Renal CellNeoplasms+10 more
Jinling Hospital, China39 enrolled1 locationNCT06676527
Recruiting

Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)

Pleural Effusion, MalignantAscites, MalignantCarcinoma+4 more
Travera Inc200 enrolled1 locationNCT05461430
Recruiting

Deep Learning for Automated Discrimination Between Stage T1-T2 and T3 Renal Cell Carcinoma on Contrast-Enhanced CT

Carcinoma, Renal CellPathologyDeep Learning+1 more
Peking University First Hospital1,000 enrolled1 locationNCT07166445
Recruiting
Phase 2

Autologous Dendritic Cell Vaccine in Kidney Cancer

Carcinoma, Renal Cell
Jodi Maranchie42 enrolled1 locationNCT05127824
Recruiting

Mechanisms of Somatic Mutation and Tumor Initiation in Pre-malignant Kidney Tubule Cells

Carcinoma, Renal CellVon Hippel-Lindau Disease
IRCCS San Raffaele50 enrolled1 locationNCT06194669
Recruiting
Phase 2

A Study of Oncobax®-AK in Patients With Advanced Solid Tumors

Carcinoma, Renal Cell
EverImmune122 enrolled4 locationsNCT05865730
Recruiting

Predicting Model Based on Evidence-based Pathological Diagnose Criteria for RCC Tumor Thrombus With IVC Wall Invasion

Carcinoma, Renal CellTumor ThrombusNeoplasm Invasiveness+1 more
Peking University Third Hospital232 enrolled1 locationNCT05589207